
Until recently, there has been little attention paid to the treatment of tricuspid regurgitation (TR) aside from small series of patients with congenital disease or infective endocarditis. This reflects both the relative rarity of ‘primary TR’, as well as the perception that most TR was felt to be ‘secondary’ to pulmonary hypertension or a cardiomyopathic process, in which case the treatment was directed towards the underlying cause...
Like
Save
Share